Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical TrialsPiotr Rutkowski, Scott M. Schuetze, Alexander J. Lazar et al.|Journal of Clinical Oncology|2010Cited by 401
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing ResultsMichael C. Heinrich, Laurence H. Baker, Cathryn Rankin et al.|JAMA Oncology|2017Cited by 126
Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trialMartin E. Blackstein, George D. Demetri, Ernest C. Borden et al.|Journal of Clinical Oncology|2005Cited by 17